FDA DEVICE FACTS
Hintermann Series H2 Total Ankle System
Dt Medtech, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Complete original indications and intended use
The Hintermann Series H2 Total Ankle Replacement (Hintermann Series H2) system is designed to treat ankle arthritis through replacement of the ankle joint with a prosthesis, thereby reducing pain, restoring alignment, replacing flexion and extension movement in the ankle joint, and allowing for movement at the replaced joint. The Hintermann Series H2 is indicated as a to tal ankle replacement in primary or revision surgery of ankle joints damaged by:
• Systemic arthritis of the ankle (e.g., rheumatoid arthritis, hemochromatosis)
• Primary arthritis (e.g., degenerative disease)
• Secondary arthritis (e.g., post‐traumatic, avascular necrosis, provided enough of the talus is preserved to support the implant) The Hintermann Series H2 is also indicated for patients with a failed pr evious ankle surgery and revision surgeries following failed total ankle replacement or non‐union/mal‐union of the ankle arthrodesis, provided sufficient bone stock is present. Note: In the United States, this device is intended for cement ed use only.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。